Stockscreener 앱 받기
27.36
0.55%
-0.15
시장 영업 전:
27.37
0.01
+0.04%
전일 마감가:
$27.51
열려 있는:
$27.495
하루 거래량:
1.56M
Relative Volume:
0.67
시가총액:
$2.78B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-15.12
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
+1.00%
1개월 성능:
+25.10%
6개월 성능:
+56.88%
1년 성능:
-2.49%
1일 변동 폭
$26.83
$27.91
1주일 범위
$25.86
$28.28
52주 변동 폭
$13.53
$35.25
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.36 | 2.79B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Nikko Asset Management Americas Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Bellevue Group AG Raises Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
Beam Therapeutics Inc. $BEAM Holdings Lowered by Redmile Group LLC - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Evercore ISI Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
Beam Therapeutics (BEAM) Receives a Buy from Bank of America Securities - The Globe and Mail
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
Beam Therapeutics stock rises on promising sickle cell therapy data By Investing.com - Investing.com Nigeria
Beam Therapeutics stock rises on promising sickle cell therapy data - Investing.com
(BEAM) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Reveals Positive Trial Results at Hemat - GuruFocus
Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON Sickle Cell Trial Results and Renewed Momentum - Yahoo Finance
Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential - Yahoo Finance
Beam reports positive data from sickle cell disease gene therapy trial By Investing.com - Investing.com South Africa
Beam reports positive data from sickle cell disease gene therapy trial - Investing.com
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Reports Promising Updates on Risto-cel for Sickle Cell Disease at 67th ASH Annual Meeting - Quiver Quantitative
38,438 Shares in Beam Therapeutics Inc. $BEAM Purchased by Capital Fund Management S.A. - MarketBeat
Beam Therapeutics stock surges 64% since InvestingPro’s April undervalued call By Investing.com - Investing.com Australia
BEAM (Beam Therapeutics) Capex-to-Operating-Income : 0.00 (As of Sep. 2025) - GuruFocus
How Beam Therapeutics Inc. stock compares to industry benchmarksProfit Target & AI Powered Market Entry Strategies - Newser
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 6.8%What's Next? - MarketBeat
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? - Yahoo Finance
Published on: 2025-12-04 06:37:06 - Newser
Why analysts remain bullish on Beam Therapeutics Inc. stockJuly 2025 Trends & Community Verified Trade Signals - Newser
Beam Therapeutics (BEAM) Experiences Significant Stock Surge - GuruFocus
Will Beam Therapeutics Inc. stock split again soonSell Signal & Daily Volume Surge Trade Alerts - Newser
Will Beam Therapeutics Inc. stock pay special dividends2025 Stock Rankings & Precise Swing Trade Entry Alerts - Newser
Is Beam Therapeutics Inc. stock attractive for ETFsRate Cut & Safe Entry Point Identification - Newser
The Best CRISPR Companies for 2025 - The Motley Fool
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - MSN
Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors - MSN
Geode Capital Management LLC Grows Position in Beam Therapeutics Inc. $BEAM - MarketBeat
14,601 Shares in Beam Therapeutics Inc. $BEAM Bought by Entropy Technologies LP - MarketBeat
Beam Therapeutics (BEAM) Earnings Transcript - Nasdaq
How resilient is Beam Therapeutics Inc. stock in market downturnsOil Prices & Stepwise Swing Trade Plans - BỘ NỘI VỤ
Is Beam Therapeutics Inc. stock a defensive play in 20252025 Winners & Losers & Free Technical Pattern Based Buy Signals - BỘ NỘI VỤ
(BEAM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
ETFs Investing in Beam Therapeutics Inc. Stocks - TradingView
Evercore ISI Group Initiates Coverage of Beam Therapeutics (BEAM) with Outperform Recommendation - MSN
Beam Therapeutics Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Beam Therapeutics (BEAM) Receives New 'Outperform' Rating from E - GuruFocus
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
How Beam Therapeutics Inc. stock valuations compare to rivals - newser.com
Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):